Latest Updates
On May 8, 2026, Pharmacal of Jackson, Wisconsin announced a voluntary recall of one lot of MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream. The FDA published the recall announcement on May 12, 2026 [1]. No adverse events related to this recall have been reported to date.
What Products Are Affected?
The recall covers one specific lot of MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream sold in a 6 oz tube. The affected product can be identified by the following information:
- Product Code: 5106
- UPC: 012277051067
- Lot Number: 1024088 (located in the crimped end of the tube)
- Expiration Date: November 2026
The recalled product was distributed nationwide to wholesale distributors, retail locations including H-E-B grocery stores, and internet retailers including Amazon.
What Is the Hazard?
The recalled cream has been found to be contaminated with Staphylococcus aureus, a bacterium that can cause a range of infections from localized to severe or life-threatening. Patients with weakened immune systems or compromised skin — such as those with wounds, burns, or underlying skin disorders — face the greatest risk of serious harm.
Use of the contaminated product could lead to skin and skin structure infections, infective endocarditis, bone and joint infections, bloodstream infections, and life-threatening conditions such as sepsis and septic shock.
What Caused the Recall?
Pharmacal discovered that the affected lot of MG217 cream was contaminated with Staphylococcus aureus. The company is notifying its distributors via written correspondence and is arranging for the return of all recalled products. The recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
What Should Consumers Do?
Consumers who have the recalled lot of MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream should immediately stop using the product and discard it. Consumers who have experienced any problems potentially related to this product should contact their physician or healthcare provider.
Consumers with questions may contact Pharmacal at 800-558-6614 or by email at aimho@pharmacalway.com, Monday through Friday, 8:00 a.m. to 5:00 p.m. Central Time. Adverse reactions may also be reported to the FDA’s MedWatch program at 1-800-332-1088.
Can I File a Lawsuit?
Consumers who purchased the recalled MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream — or who suffered an adverse reaction as a result — may have legal options. A class action lawsuit could allow affected consumers to seek compensation for medical expenses, lost wages, and other related losses. Contact an attorney to learn more about your rights.
References
1. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pharmacal-issues-nationwide-recall-mg217-multi-symptom-treatment-cream-skin-protectant-eczema-cream